Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study

To date, there are no specific therapeutic strategies for treatment of COVID-19. Based on the hypothesis that complement and coagulation cascades are activated by viral infection, and might trigger an acute respiratory distress syndrome (ARDS), we report clinical outcomes of 17 consecutive cases of...

Descripción completa

Detalles Bibliográficos
Autores principales: Giudice, Valentina, Pagliano, Pasquale, Vatrella, Alessandro, Masullo, Alfonso, Poto, Sergio, Polverino, Benedetto Maria, Gammaldi, Renato, Maglio, Angelantonio, Sellitto, Carmine, Vitale, Carolina, Serio, Bianca, Cuffa, Bianca, Borrelli, Anna, Vecchione, Carmine, Filippelli, Amelia, Selleri, Carmine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291857/
https://www.ncbi.nlm.nih.gov/pubmed/32581810
http://dx.doi.org/10.3389/fphar.2020.00857

Ejemplares similares

Ejemplares similares